Biomerica Stock Current Valuation
| BMRA Stock | USD 0.39 0.07 21.88% |
Valuation analysis of Biomerica helps investors to measure Biomerica's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The current year's Enterprise Value is expected to grow to about 9.1 M, whereas Enterprise Value Over EBITDA is forecasted to decline to (1.12). Fundamental drivers impacting Biomerica's valuation include:
Price Book 1.2256 | Enterprise Value 4.4 M | Enterprise Value Ebitda (5.42) | Price Sales 1.1893 | Enterprise Value Revenue 0.8058 |
Undervalued
Today
Please note that Biomerica's price fluctuation is very risky at this time. Calculation of the real value of Biomerica is based on 3 months time horizon. Increasing Biomerica's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Biomerica is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Biomerica Stock. However, Biomerica's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.39 | Real 3.52 | Target 13.0 | Hype 0.39 | Naive 0.35 |
The real value of Biomerica Stock, also known as its intrinsic value, is the underlying worth of Biomerica Company, which is reflected in its stock price. It is based on Biomerica's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Biomerica's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Biomerica helps investors to forecast how Biomerica stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Biomerica more accurately as focusing exclusively on Biomerica's fundamentals will not take into account other important factors: Biomerica Company Current Valuation Analysis
Biomerica's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Biomerica Current Valuation | 4.44 M |
Most of Biomerica's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biomerica is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Biomerica Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Biomerica is extremely important. It helps to project a fair market value of Biomerica Stock properly, considering its historical fundamentals such as Current Valuation. Since Biomerica's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Biomerica's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Biomerica's interrelated accounts and indicators.
Click cells to compare fundamentals
Biomerica Current Valuation Historical Pattern
Today, most investors in Biomerica Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Biomerica's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Biomerica current valuation as a starting point in their analysis.
Biomerica Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Biomerica has a Current Valuation of 4.44 M. This is 99.97% lower than that of the Health Care Equipment & Supplies sector and 99.96% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.97% higher than that of the company.
Biomerica Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biomerica's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biomerica could also be used in its relative valuation, which is a method of valuing Biomerica by comparing valuation metrics of similar companies.Biomerica is currently under evaluation in current valuation category among its peers.
Biomerica Current Valuation Drivers
We derive many important indicators used in calculating different scores of Biomerica from analyzing Biomerica's financial statements. These drivers represent accounts that assess Biomerica's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Biomerica's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 64.6M | 43.5M | 44.4M | 19.4M | 9.8M | 10.3M | |
| Enterprise Value | 57.7M | 41.0M | 39.8M | 10.8M | 6.4M | 9.1M |
Biomerica Fundamentals
| Return On Equity | -0.76 | ||||
| Return On Asset | -0.39 | ||||
| Profit Margin | (1.12) % | ||||
| Operating Margin | (0.76) % | ||||
| Current Valuation | 4.44 M | ||||
| Shares Outstanding | 16.82 M | ||||
| Shares Owned By Insiders | 7.21 % | ||||
| Shares Owned By Institutions | 13.01 % | ||||
| Number Of Shares Shorted | 371.65 K | ||||
| Price To Earning | (25.64) X | ||||
| Price To Book | 1.23 X | ||||
| Price To Sales | 1.19 X | ||||
| Revenue | 5.42 M | ||||
| Gross Profit | 446 K | ||||
| EBITDA | (5.99 M) | ||||
| Net Income | (5.98 M) | ||||
| Cash And Equivalents | 6.08 M | ||||
| Cash Per Share | 0.45 X | ||||
| Total Debt | 785 K | ||||
| Debt To Equity | 0.16 % | ||||
| Current Ratio | 5.22 X | ||||
| Book Value Per Share | 0.32 X | ||||
| Cash Flow From Operations | (5.36 M) | ||||
| Short Ratio | 2.28 X | ||||
| Earnings Per Share | (0.37) X | ||||
| Target Price | 13.0 | ||||
| Number Of Employees | 64 | ||||
| Beta | -1.14 | ||||
| Market Capitalization | 5.46 M | ||||
| Total Asset | 9.25 M | ||||
| Retained Earnings | (48.2 M) | ||||
| Working Capital | 5.53 M | ||||
| Current Asset | 4.77 M | ||||
| Current Liabilities | 445 K | ||||
| Net Asset | 9.25 M |
About Biomerica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biomerica's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biomerica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biomerica based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Biomerica offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomerica's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomerica Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomerica Stock:Check out Biomerica Piotroski F Score and Biomerica Altman Z Score analysis. For information on how to trade Biomerica Stock refer to our How to Trade Biomerica Stock guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomerica. If investors know Biomerica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomerica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.37) | Revenue Per Share 0.327 | Quarterly Revenue Growth 0.055 | Return On Assets (0.39) | Return On Equity (0.76) |
The market value of Biomerica is measured differently than its book value, which is the value of Biomerica that is recorded on the company's balance sheet. Investors also form their own opinion of Biomerica's value that differs from its market value or its book value, called intrinsic value, which is Biomerica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomerica's market value can be influenced by many factors that don't directly affect Biomerica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomerica's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomerica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomerica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.